Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590187 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
A Phase 2 study, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00590187 is a Phase 2 study that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT00590187, a Phase 2 study, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The objective is to treat elderly AML and MDS patients with sapacitabine.
Interventions
- DRUG Sapacitabine, Arm A
- DRUG Sapacitabine, Arm B
- DRUG Sapacitabine, Arm C
- DRUG Sapacitabine, Arm D
- DRUG sapacitabine, Arm E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2007-12 |
| Est. Completion | 2018-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590187
The ClinicalTrials.gov registry entry for NCT00590187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sapacitabine, Arm A is the first listed.
NCT00590187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590187 about?
NCT00590187 is a clinical study titled "Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients". The objective is to treat elderly AML and MDS patients with sapacitabine.
What is the current status of trial NCT00590187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2007-12. Estimated completion is 2018-12-01.
What interventions are being tested in trial NCT00590187?
The interventions under investigation include: Sapacitabine, Arm A (DRUG), Sapacitabine, Arm B (DRUG), Sapacitabine, Arm C (DRUG), Sapacitabine, Arm D (DRUG), sapacitabine, Arm E (DRUG).
Who is sponsoring clinical trial NCT00590187?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.